1. Academic Validation
  2. Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction

Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction

  • Biomed Pharmacother. 2018 Oct:106:593-598. doi: 10.1016/j.biopha.2018.06.077.
Min Luo 1 Juanmei Mo 1 Qitao Yu 2 Shaozhang Zhou 2 Ruiling Ning 2 Yu Zhang 1 Cuiyun Su 2 Hongzhi Wang 1 Jiandong Cui 3
Affiliations

Affiliations

  • 1 Department of Oncology, No. 303 Hospital of Chinese People's Liberation Army, Nanning, Guangxi 530021, China.
  • 2 Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.
  • 3 Department of Oncology, No. 303 Hospital of Chinese People's Liberation Army, Nanning, Guangxi 530021, China. Electronic address: hesnoww@sina.com.
Abstract

Non-small cell lung Cancer (NSCLC) is one of the most prevailing malignancies worldwide. It has been previously shown that wogonoside exerts anti-tumor activities in various kinds of human cancers. But its role in NSCLC remains elusive. In the present study, we determined the anti-tumor effect of wogonoside in human NSCLC A549 cells. We found that wogonoside effectively inhibits A549 cell viability through inducing cell cycle arrest and Apoptosis. Moreover, administration of wogonoside by intraperitoneal injection inhibits the growth of A549 cell xenografts in athymic nude mice. Additionally, mitochondrial membrane potential was disrupted and cytochrome c was released to cytosol in the wogonoside-treated A549 cells. Finally, we found that AMPK/mTOR signaling might be implicated in the anti-NSCLC efficacy of wogonoside. Therefore, we may assume that wogonoside may be considered as a potential therapeutic agent for the treatment of NSCLC.

Keywords

AMPK/mTOR signaling; Apoptosis; Mitochondria; Non-small cell lung cancer; Viability; Wogonoside.

Figures
Products